Modeling of Tau-Mediated Synaptic and Neuronal Degeneration in Alzheimer's Disease by Jaworski, Tomasz et al.
SAGE-Hindawi Access to Research
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 573138, 10 pages
doi:10.4061/2010/573138
Review Article
Modelingof Tau-Mediated Synaptic and Neuronal Degeneration
inAlzheimer’sDisease
Tomasz Jaworski,1 SebastianK¨ ugler,2 and Fred Van Leuven1
1Experimental Genetics Group, Department of Human Genetics, KULeuven-Campus Gasthuisberg ON1-06.602, Herestraat 49,
3000 Leuven, Belgium
2Center of Molecular Physiology of the Brain (CMPB), Department of Neurology, University Medicine G¨ ottingen, Waldweg 33,
37073 G¨ ottingen, Germany
Correspondence should be addressed to Fred Van Leuven, fred.vanleuven@med.kuleuven.be
Received 18 May 2010; Accepted 9 July 2010
Academic Editor: Gemma Casadesus
Copyright © 2010 Tomasz Jaworski et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Patients suﬀering from Alzheimer’s disease (AD) are typiﬁed and diagnosed postmortem by the combined accumulations of
extracellularamyloidplaquesandofintracellulartauopathy,consistingofneuropiltreadsandneuroﬁbrillarytanglesinthesomata.
Both hallmarks are inseparable and remain diagnostic as described by Alois Alzheimer more than a century ago. Nevertheless,
these pathological features are largely abandoned as being the actual pathogenic or neurotoxic factors. The previous, almost
exclusive experimental attention on amyloid has shifted over the last 10 years in two directions. Firstly, from the “concrete”
deposits of amyloid plaques to less well-deﬁned soluble or pseudosoluble oligomers of the amyloid peptides, ranging from
dimers to dodecamers and even larger aggregates. A second shift in research focus is from amyloid to tauopathy, and to their
mutual relation. The role of Tau in the pathogenesis and disease progression is appreciated as leading to synaptic and neuronal
loss, causing cognitive deﬁcits and dementia. Both trends are incorporated in a modiﬁed amyloid cascade hypothesis, brieﬂy
discussed in this paper that is mainly concerned with the second aspect, that is, protein Tau and its associated fundamental
questions.
1.Background
1.1. The Amyloid Problem. Amyloid peptides are derived
from the amyloid precursor protein (APP) by sequential
proteolytic cleavages by β-a n dγ-secretases [1, 2]. Amyloid
peptides, particularly the longer Aβ42 species, aggregate into
various and diﬀerent chemical or physical entities, which
are now considered the primary pathological agents in AD.
Controversial experimental data leave nevertheless many
questions open with regards to the exact composition and
size of the amyloid oligomers in vivo [3–5]. Moreover, the
precise molecular actions of the amyloid peptides and their
aggregates remain unknown and enigmatic, largely because
their molecular targets, or their speciﬁc receptors remain
undeﬁned. This issue raises more fundamental questions.
Forone,whiletheproteolyticenzymesandtheirmechanisms
responsible for the generation of the amyloid peptides
become well-known and understood at the molecular level,
the eventual physiological function of the peptides is still
questioned—and remains questionable.
The original pathological importance ascribed to amy-
loid plaques was weakened, if not eliminated based on infor-
mation gathered in transgenic models expressing mutant
APP. We have advocated this hypothesis since we discovered
early defects in cognition and LTP in APP.V717I mice [6–
11]. Matters are, however, complicated further by recent
data originating from several clinical trials that identiﬁed
a large fraction of individuals in the control groups with
considerablebrainamyloidloadusingPET-imaging[12–14].
Obviously, this means that high-amyloid concentration in
the brain is not per se incompatible with normal cognitive
functioning in old age. This calls for other factors to be
at least coresponsible for the cognitive demise in AD-
forwarding protein Tau as the most obvious candidate.2 International Journal of Alzheimer’s Disease
1.2. Tauopathy: Not Primary but Secondary in AD. Primary
Tauopathy is recognized in a vast and still increasing number
ofCNS-disorders.Thepathologyisvisualizedpostmortemas
intraneuronal aggregates of protein Tau, known as neuropil
treads and neuroﬁbrillary tangles. These are similar if not
identical to those observed in AD brain and mostly present
without other associated pathological hallmarks, except
inﬂammation markers. The large clinical variability among
the primary Tauopathies stems from the presence of the
Tau pathology in diﬀerent types of neurons and in diﬀerent
brain-regions [15–18].
Biochemically, all Tauopathies consist of smaller and
larger aggregates and ﬁbrils that become intertwined to form
larger tangles in the soma as well as in axons and dendrites of
aﬀectedneurons.Theaggregatesconsistalmostexclusivelyof
protein Tau, albeit as diﬀerent isoforms in diﬀerent diseases,
that is, either Tau.3R or Tau.4R or as a variable admixture.
Their widely diﬀerent grading of phosphorylation is usually
referred to as hyperphosphorylated Tau, denoted here as hP-
Tau. Importantly, no accurate deﬁnition based on either the
level or the speciﬁc phosphorylated residues can typify any
Tauopathy exactly, because of the large variability with each
primary disease.
Most primary Tauopathies are sporadic. Rare familial
cases of frontotemporal dementia (FTD) are linked to
exonic and intronic mutations in the MAPT gene coding
for protein Tau (chromosome 17). Although rare, their
identiﬁcation marked a major breakthrough and boosted
interestinTauopathy,becauseoftheevidentimplicationthat
Tauopathy itself is suﬃcient to cause cognitive decline and
dementia [15, 16, 18–21].
Both intronic and exonic mutations have important
mechanistical implications: (i) most expressed mutations are
in the microtubule binding domain of Tau; (ii) intronic
mutations promote or hinder splicing of exon 10 coding
for the second repeat domain in the microtubule binding
domain, skewing expression of isoforms to either Tau3R or
Tau4R, but both with normal sequences and consequently
normal binding-aﬃnity for microtubules.
The pathology resulting from intronic mutations in the
MAPTgenecanonlybeexplainedbyeﬀectsonRNAsplicing,
eventuallyresultinginchangesinabsoluteorrelativelevelsof
Tau isoforms that otherwise have normal wild-type protein
sequences. The overexpression or overrepresentation of one
or the other Tau isoform can then be extrapolated to the
primary Tauopathies that are sporadic, as well as to sporadic
AD as the most prominent secondary Tauopathy involving
normal, wild-type Tau-isoforms.
1.3. The Obligate Amyloid-Tau Relation. The major unre-
solved problem in AD is the mechanistic relation of amyloid
and Tau pathology. Amyloid oligomers are proposed to
precede, and eventually trigger the intracellular Tauopathy,
likely by increasing the phosphorylation of protein Tau [11,
15, 17, 22]. While this hypothesis remains at this moment in
timeimpossibletoproveinsporadicADcases,itissupported
byextrapolationofobservationsinfamilialADcases.Indeed,
even in the most early onset familial AD that are caused by
mutantPresenilinormutantAPP,andthereforebydeﬁnition
are “amyloid-triggered”, Tauopathy is always evident and
codiagnostic. Experimentally, double and triple transgenic
mouse models with combined amyloid and Tau-pathology
prove the same intimate relation [23–26].
The genetic data imply that deranged Tau-microtubule
interactions, caused either directly by the mutation, by phos-
phorylation, by increased absolute or by disturbed relative
concentrationsofTau,allcancontributeorevenbesuﬃcient
to cause neurodegeneration in primary Tauopathies, that is,
in the absence of amyloid pathology. Importantly, experi-
mental decrease of the level of Tau in amyloid transgenic
mice can actually ameliorate several clinical symptoms and
defects [27]. The combined data further corroborate the
hypothesis that protein Tau is essentially contributing to
amyloid-induced cognitive defects.
Not resolved are the identity and exact nature of the
receptors and associated signaling pathways that lead from
amyloid to Tau. These pathways obligatory involve kinases
such as GSK3 [25, 26] that contribute, directly or indirectly
to the phosphorylation of Tau at residues that aﬀect its
binding to microtubuli. This is thought, but not proven,
to instigate its eventual aggregation into ﬁbrils that are
deposited locally as neuropil treads or transported to the
soma and form the neuroﬁbrillary tangles, and both types
of aggregates occur in the same neurons. Nevertheless,
Tauopathy does not per se cause immediate or even delayed
neuronal death, as tangled and Tau-loaded neurons are
observed in humans as well as in experimental models, that
is, transgenic mice, zebra-ﬁsh, and ﬂies [26, 28, 29].
The pertinent question to be answered then is: what
chemicalorphysicalformofproteinTaucausessynapto-and
neurodegeneration?
2.Transgenic andAdeno-Associated
Virus Models
Invaluable insight in the problems that we are concerned
with, have resulted from analyzing diﬀerent transgenic
mousemodels.Ourresearch-groupgenerated,characterized,
and validated many diﬀerent transgenic mouse strains and
their bigenic combinations as preclinical models over the last
two decades. So far none of the models recapitulates robustly
the evident neurodegeneration observed in the brain of AD
patients.
We explored and reported on additional models to
increase our understanding of this aspect of the pathogenesis
of AD [11, 30]. Here, we review data and insights obtained
with adeno-associated viral vectors that were engineered
to express wild-type or mutant APP or protein Tau in
pyramidal neurons of the hippocampus of wild-type mice.
Thereby, we aimed to recapitulate aspects of AD pathology
and related features that are not attainable in transgenic
mice, particularly neurodegeneration.
Among the diﬀerent viral vectors available, we selected
AAV because these have been demonstrated as excellent
and safe tools for gene delivery into the CNS. Recent
technical advances have improved AAV-based vectors asInternational Journal of Alzheimer’s Disease 3
Figure 1: Expression of EGFP following hippocampal injection of
AAV1/2.EGFP is long-lasting. Six months following intracerebral
injectionoftheAAV.EGFPvector,thetransgeneremainedexpressed
in the CA1/2 subﬁelds of the hippocampus and in the deeper layers
of the cortex. Expression of EGFP is also evident in and likely
propagates along axonal projections of the fornix.
t o o l si nn e u r o n a lr e s e a r c h[ 31, 32]. The expression of the
human transgenes used in our studies was controlled by the
human Synapsin1 gene promoter, with constructs packed
in chimeric capsids AAV1/2, expressing eﬃciently in pyra-
midal neurons of the CA1/2 subﬁeld of the hippocampus
(Figure 1). Control AAV vectors expressed EGFP in the
designated neurons and areas that persisted for months
without negative signs or symptoms (Figure 1)a n d[ 31, 32].
2.1. Amyloid Pathology without Neurodegeneration. We ﬁrst
constructed AAV vectors to recapitulate the amyloid pathol-
ogy in the limbic region of wild-type mice. The constructs
contained APP695 as the most abundant neuronal isoform,
either as wild type sequence or as the engineered triple
mutant (denoted APP.SLA). The incorporated Swedish,
London and Austrian mutations are each associated with
familial forms of AD [33–35].
Following intracerebral injection into wild-type mice,
the APP.SLA mutant produced a gradual accumulation of
APP and amyloid peptides in pyramidal neurons in the
hippocampal CA1/2-region, as well as in the deeper layers
of the neighboring cortex. Similar expression of wild-type
human APP695 failed to produce any deposition of amyloid
or of the related eﬀects observed with mutant APP.SLA [30].
Initially, from 3 weeks to 3 months postinjection (p.i.),
amyloid immunoreactivity appeared as intracellular inclu-
sions or vacuolar bodies inside pyramidal neurons. At 6
months p.i., amyloid plaques developed as immunoreactive
and thioﬂavinS positive deposits in the hippocampus and
cortex (Figure 2). At this late time-point, we also observed
increased phosphorylation of endogenous mouse protein
Tau, particularly at residues T181 and T231, both known to
be substrate for GSK3. These phosphoepitopes, deﬁned by
antibodies AT270 and AT180 were diﬀerentially expressed,
that is, in hippocampal pyramidal neurons (T231) and in
dystrophic neurites around amyloid plaques (T181).
In contrast, Intracerebral injection of AAV-APP.SLA not
in wild-type but in Tau.P301L mice led to the formation
of neuroﬁbrillary tangles (NFT), demonstrating that the
viral assault did not prevent protein Tau from forming
tangles (Figure 2). Moreover, the combination demonstrated
that besides the primary hit, also the receiving genetic
background is of utmost importance. Most interesting for
the interpretation of the data obtained with protein Tau,
discussed in the next section, was the observation that at 6
months p.i. the phosphorylation of endogenous mouse Tau
was increased and coincided with a minor but signiﬁcant
reduction in the number of neurons in the CA1 region of
AAV-APP.SLA injected mice [30].
2.2. Tau-Mediated Pyramidal Neurodegeneration without
Tauopathy. In second instance, we similarly expressed either
wild-type Tau.4R or mutant Tau.P301L by AAV-vectors
in wild-type mouse brain. In sharp contrast to APP-SLA,
AAV-mediated expression of protein Tau resulted already
at 3 weeks p.i. in marked neurodegeneration of pyramidal
neurons in CA and adjacent cortical layers [30]. These
ﬁndings were rather unexpected and we analyzed them in
diﬀerent directions, yielding novel and important insight
into the mechanisms causing neuronal death by protein Tau.
Most remarkably, we could not detect any major form
of aggregates of protein Tau in pyramidal neurons that
expressed either wild-type or mutant protein Tau. Extensive
analysis by histochemistry and immunohistochemistry with
a panel of indicator compounds and monoclonal antibodies
to protein Tau, did not reveal any appreciable signs of
formation of intraneuronal Tau-aggregates, either before or
during or after the pyramidal neurons in CA1/2 succumbed
[30].
The observed neurodegeneration was not due to massive
overexpression of human protein Tau. The actual levels
in hippocampal extracts were near-physiological and only
about twice those of endogenous mouse Tau4R. Note that
also in the AAV-APP.SLA model described in the previous
section, the hippocampal levels of human APP.SLA were
only about twice those of endogenous murine APP. In
addition, expression of EGFP by the same AAV-type vectors
proved harmless to pyramidal neurons over long time-
periods (Figure 1)a n d[ 30, 31].
Intracerebral injection of 3- and 10-fold less AAV-Tau,
with consequently less expression of human protein Tau,
produced a graded, lesser loss of hippocampal neurons [30].
The AAV-Tau-induced neurodegeneration is thereby further
demonstrated to be directly caused by and proportional to
the near-physiological levels of protein Tau.
Consequently, the observed pyramidal cell-death is qual-
iﬁedasspeciﬁcforhumanproteinTau.Thisconclusionholds
up for wild-type Tau.4R and for mutant Tau.P301L, making
the model at least conform the observations in familial FTD.
Indeed, as discussed above, intronic and exonic mutations
yield very similar clinical outcome, despite the expression
of mutant or wild-type Tau4R, respectively. The actual4 International Journal of Alzheimer’s Disease
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Figure 2: Protein Tau is activated by and therefore downstream of amyloid pathology. (a) Tau.P301L transgenic mice [36] were injected
intracerebrally at age 1.5 months with either AAV-APP.SLA vector (10e8 tu) or with AAV-EGFP as control. At 6 months p.i. the expression of
APP.SLA, unlike EGFP, led to formation of amyloid aggregates and plaques, as shown by histochemical staining with X34 (lower left panel).
The mutant APP.SLA also strongly increased the phosphorylation of transgenic Tau.P301L resulting in the formation of neuroﬁbrillary
tangles already at this age of the Tau.P301L mice in pyramidal neurons of CA1: immunohistochemistry with Mab AT180 speciﬁc for
phospho-T231-Tau (upper panels), Mab MC1 (conformational Tau-epitope) (middle panel left) and Mab AT100 (phospho-S212/T214)
(middle panel right). Remarkably, the amyloid plaques and Tau pathological aggregates coexist in AAV-APP.SLA-injected Tau.P301L mice
without causing appreciable neurodegeneration. (b) Intracerebral injection of AAV-Tau.P301L (10e8 tu) in wild-type mice produced
extensive neurodegeneration of CA1 pyramidal neurons as shown before [11]. Aggregates of Tau or tangles were very rare although they
can form in these neurons in the experimental conditions, as shown histochemically with compound X34 as sensitive probe for β-sheeted
aggregated protein [12, 14]. Clearly, the paucity of tangles cannot explain the extensive neuronal cell death. Degenerating neurons share
morphological features of necrosis and autophagy, with extensive vacuolization as demonstrated histochemically by toluidin blue staining
(bottom panel).
contribution of the mutation to the mechanism underlying
the pathogenesis requires a rational explanation in human
FTD patients, as well as in the AAV-models.
3.MechanismsUnderlyingTau-Mediated
PyramidalNeurodegeneration
Extensive analysis to deﬁne the mechanisms that underlie
the observed Tau-mediated pyramidal neurodegeneration
are described, summarizing reported data and preliminary
data of work in progress.
Similar AAV-mediated expression of a truncated version
of protein Tau.4R, lacking the microtubule binding C-
terminal domain, proved completely harmless and did not
cause any neurodegeneration over similar time-periods [30].
The inherent conclusion must be that microtubule binding
of protein Tau is essentially involved in the neurotoxic
degenerative mechanism. Consequently, we must orient
further analysis to mechanisms that involve axonal and
dendritic transport over microtubuli, which is of paramount
importance for all cells but especially for neurons with their
intricate branching.
Of note, microgliosis was observed to be intense, and
spatially and temporally closely associated with AAV-Tau
induced degenerating neurons [30]. This was most recently
also reported in a similar model based on AAV vectors but
in rats and for a diﬀerent pathology in a diﬀerent brain-
region[38].Previously,wehaveobservedasimilarrelationof
microgliosis to neurodegeneration in an unrelated model forInternational Journal of Alzheimer’s Disease 5
hippocampal sclerosis, caused by conditional expression of
p25,thetruncatedactivatorofcdk5[39].Also,inthatmodel,
intenseneurodegenerationwasnotmarkedbyaggregationof
protein Tau, further strengthening our conclusion that cdk5
is not a major Tau-kinase in vivo [39–41].
The data originating from the AAV-models led us to
conclude that not large aggregates of protein Tau cause
neurodegeneration [30]. This conﬁrms our observations in
transgenic mice that show aggregation of Tau leading to
Tauopathy in somata and neuropil, but not accompanied by
marked neurodegeneration [25, 26, 36].
We proposed that neurons aﬀected by Tauopathy can
either engage in aggregation of Tau and thereby try to
decrease the toxic species and hope to survive, or to enter
the “path to death” by failing to aggregate protein Tau
[11]. Clearly, the viral models comply with the transgenic
models that aggregation of Tau and neurodegeneration are
not closely linked. Thereby, questions are raised that are
addressed in more detail in the next sections.
3.1. What is the Neurotoxic Tau-Species?
The classic concept that Tau-ﬁbrils or tangles are neuro-
toxic in Tauopathies can be abandoned. We advocate that
neuroﬁbrillary tangles, like amyloid plaques are the ﬁnal
pathological hallmarks, but not the neurotoxic agents. The
outcome ﬁts independent observations that the extent of
neuronal loss exceeds the number of NFT in patients with
AD [42, 43]. In inducible Tg4510 mice, memory decline and
neuronal loss are dissociated from tangle formation in time
and brain region [44, 45].
In the AAV-Tau injected mice, phosphorylation of Tau
was evident at many pathological epitopes, including those
deﬁned by antibodies AT8, AT100, AT180, and AT270
[30]. Despite the increased phosphorylation no aggregates
of protein Tau were deposited in degenerating pyramidal
neurons, analyzed histochemically or immunohistochemi-
cally. Biochemical analysis indicated the formation of low
molecular weight aggregates [30] which need and deserve
further analysis.
Intriguingly, experiments whereby AAV-APP.SLA was
injected intracerebrally not in wild-type mice but in
transgenic Tau.P301L mice, produced not only amyloid
plaques but also intracellular Tau aggregates. Nevertheless,
no substantial neuronal loss was evident, substantiating
our previous data of absence of marked neurodegeneration
in Tau.P301L mice and Tau.P301LxGSK3b bigenic mice
(biGT), despite extensive or even dramatic Tauopathy [26,
36].
Thecombinedresultsfromourexperimentalmodelsand
from a Drosophila model of Tauopathy [46] consolidates the
thesis that neurotoxicity is not exerted by large aggregates of
protein Tau but rather by Tau-species that are intermediate
between normally phosphorylated protein Tau and the
hyper-phosphorylated ﬁbrils. The identity of the toxic Tau
species, which we have termed “Tau-P∗”[ 11, 30] remains to
be deﬁned—a challenge equaling that of the identiﬁcation of
the amyloid receptor.
It must be remembered that Tau is subject to other
posttranslational modiﬁcations, besides phosphorylation.
Indeed, Tau can be ubiquitinated, truncated, glycosylated,
glycated, oxidized, and, moreover, undergoes isomerization
at proline residues. At any given moment protein Tau is
present in various molecular forms, which most likely diﬀer
subtly in properties of binding to microtubuli, interaction
with other proteins, binding to membranes, being trans-
ported for normal duty or for degradation.
The decision whether neurons will enter the cell death
path or protect itself by forming Tauopathy, must depend
on the actual levels of protein Tau and on its modiﬁcations.
The rapid accumulation of Tau-P∗ will lead to cell death,
while more gradual accumulation of Tau-P∗ would result
in formation of aggregates. Both pathways will be aﬀected
by various external factors, for example, inﬂammation,
amyloid, stress, and so forth. In this concept, the aggregation
of Tau acts as the “escape from cell death pathway”.
Evidence from patients, whereby CA1 hippocampal neurons
survive for decades despite neuroﬁbrillary tangles [47]a n d
experimental animals show tangle bearing neurons survive
[26], even with lost membrane integrity [48].
3.2. Protein Aggregation, Impaired Clearance?
Two major pathways are responsible for removal of dam-
aged, unfolded, or aggregated cellular proteins: the ubiqui-
tin/proteasome system and the autophagy/lysosomal system
that also can remove aged or damaged organelles. Malfunc-
tion of autophagy can result in accumulation of protein
aggregates that may contribute to the disease pathology in
AD and other neurodegenerative disorders [49–52]. Stim-
ulating autophagy pharmacologically, for example, by inhi-
bition of mTOR, ameliorates cognitive deﬁcits and reduces
amyloid and Tau pathology in the 3xTg mouse model for
AD [53]. Autophagosomes form in a stepwise process that
requires transport over the microtubular network, which is
known to be aﬀected by protein Tau, a major microtubule-
associated protein.
In our mouse models, we did however not detect
clear indications for problems with autophagy. Degenerating
neurons in the AAV-Tau.P301L injected mice displayed
as dark neurons with extensive vacuolization that could
be taken to indicate a defective autophagic process. A
similar facet of neurons we observed in an unrelated mouse
model, that is, the p25 inducible mice that recapitulate
hippocampal sclerosis [39]. The combined data do lend
more support to the hypothesis that vacuolization is a
correlate or consequence of the degenerative process, as an
intrinsic mechanism needed to clean up defective organelles,
protein aggregates or even entire dead or dying neurons.
Consistent with this view is our observation in the AAV-
Tau.P301L mice that vacuoles do not form early in the
disease process but only after the neurons are already
degenerating [11, 30]. Finally, we searched but did not
ﬁnd biochemical evidence for the conversion of LC3-I to
LC3-II, which is generally accepted as the necessary step
in and read-out of the increased formation of autophago-
somes.6 International Journal of Alzheimer’s Disease
3.3. Cell Cycle Reentry, or Not?
After diﬀerentiation from neuronal precursors, neurons
enter their post-mitotic state, while attempts to reenter the
cell cycle is considered pathological and eventually result
in cell death. In AD and other Tauopathies, cell-cycle
related events have been suggested to be directly related to
neurodegeneration.
We tested this hypothesis in the AAV-Tau model by
examining cell cycle-related markers. Various markers were
increased, that is, CyclinD2, phosphorylated Retinoblastoma
protein, proliferating cell nuclear antigen (PCNA), cyclin
B1 [30]. However, intracerebral injection of AAV-Tau in
cyclinD2 deﬁcient mice showed no extra eﬀect on neurode-
generation, suggesting that cell cycle reentry is not a pre-
requisite for neuronal death [30].
3.4.MicrotubularTransport. Theonlyphysiologicalfunction
for protein Tau is binding to and stabilization of micro-
tubules. Microtubules ensure cell shape and constitute roads
of transport, a feature prominent in neurons with the most
complex architecture of all cells. Microtubule dependent
transport is ensured by families of motor proteins dyneins
and kinesins, respectively for retrograde transport from
distal processes towards soma and as plus-end directed
motor for anterograde transport.
The eﬀect of protein Tau on transport appears to be dual.
First, mutant Tau and hP-Tau can cause it to detach from the
microtubules and decrease its ability to control microtubule
dynamics. On the other hand, increased levels of protein Tau
can saturate microtubules and hinder the “foot-stepping”
of the motor proteins needed for axonal and dendritic
transport. Both aspects of Tau-related transport deﬁcits have
been observed and both can ﬁt into a model leading to
“starving synapses” that eventually culminates in neuronal
death. In this hypothesis, Tau-mediated neurodegeneration
is likely to start in distal neuronal processes, that is, axons
and apical dendrites, which degenerate progressively towards
the cell soma [54].
Synaptic pathology could be an early defect in neurode-
generative Tauopathies [55] as proper functioning of distal
synapses is totally dependent on adequate transport of essen-
tial cargos and uninterrupted provision of energy. Impaired
oxidative phosphorylation and mitochondrial dysfunction
has been observed in mouse models expressing mutant Tau,
which was potentiated by mutant APP and Presenilin1 [56,
57].
In Tau.4R transgenic mice, we previously documented
axonopathy and motor deﬁcits that were rescued by coex-
pression of constitutively active GSK3b [37, 58]. The data
explain how excess Tau in ﬁrst instance blocks transport
by covering microtubuli, while GSK3 acting as major
Tau-kinase I phosphorylates Tau to detach it from the
microtubules and relieves the transport blockade [37].
Interestingly, treatment of Tau.4R mice with lithium salts
signiﬁcantly increased the axonopathy, an eﬀect that can be
ascribed to its inhibition of GSK3b [59].
As discussed above, AAV-mediated expression of trun-
cated Tau, lacking the microtubule binding domain did not
cause neurodegeneration, in marked contrast to full length
protein Tau (Figures 3 and 4)a n d[ 30]. The combined
data from various approaches allow us to conclude that
Tau mediated pathology is, at least in part, mediated by its
microtubule binding properties.
3.5. Inﬂammation. Chronic inﬂammation is evident in brain
of AD patients and proposed to contribute essentially to
the “vicious circle” leading eventually to neuronal death,
brain atrophy and severe dementia. CNS-related features
of the immune system remain hardly understood, and
supposed to be “janus-faced”, that is, providing protection
as well as causing damage, steered by complex mostly
unknown control mechanisms [60, 61]. Protection could
be impaired in AD, fueled by—and fueling—debates on
possible prevention or therapeutic beneﬁts of antioxidants,
radical scavengers, nonsteroidal anti-inﬂammatory drugs
(NSAID), and so forth, although clinical trials do not
substantiate the claims.
Microglia are immunocompetent cells that enter brain
during developing as immature macrophages. They react
rapidly to brain damage, including amyloid pathology in
AD. Amyloid deposits attract microglia in a phagosomal
attempt of their elimination, but activated microglia release
proinﬂammatory cytokines, chemokines, reactive oxygen
species, prostaglandins, and other mediators that harm
neurons. Much attention has been paid to neurotoxicity
mediated by free radicals, both reactive oxygen and nitrogen
species, released by microglia.
Astrocytes are the most common cell-type in the brain,
involved in many functions and increasingly appreciated
also in synaptic signaling and integrity. Astrocytes co-
localize with microglia at damage-sites, but remain to be
exploredindetailinAD.Strictlyspeaking,neuronsmustalso
be considered when discussing neuroinﬂammation because
they (can) produce active factors, that is, complement,
interleukins, tumor necrosis factor, acute-phase proteins.
We observed and discussed that degenerating neurons
were temporally and spatially closely associated with acti-
vated microglia in two independent models, that is, the AAV-
Tau viral model and the p25 transgenic model [30, 39].
Too many “unknowns” prevent us from answering
the question how Tau-mediated damage can lead to neu-
rodegeneration by involving activation of microglia. We
maintain the most straightforward hypothesis, that is, that
the expression of protein Tau, either wild-type or mutant
by the viral vectors, is imposing stress on the pyramidal
neurons that cannot adapt rapidly enough to produce Tau-
aggregates as a means of temporarily detoxiﬁcation. The
impact on various neuronal functions is evident, including
disturbances in post-mitotic state and cell-cycle control,
as well as disturbing microtubule-mediated transport. The
latter is most destructive in axons and larger dendrites,
compromising the major synapses that become dys- or non-
functional. Secreted neuronal proteins then activate nearby
microglia that counter-react by secreting proinﬂammatory
and potentially neurotoxic factors, fueling the viscous cycle
that eventually leads to neuronal death.International Journal of Alzheimer’s Disease 7
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Figure 3: Tau-mediated toxicity depends on the microtubule binding domain. Intracerebral injection of AAV-Tau.255 (10e8 tu) into wild-
type mice to express a truncated form of protein Tau devoid of the microtubule binding and C-terminal domains, did not cause appreciable
neurodegenerationnorinﬂammation.Shownareimmunohistochemicalstainingsat3monthsp.i.forhumanTau(HT7),GFAP,andMHCII
as indicators of astrogliosis and microgliosis, respectively [30]. Neurons expressing truncated protein Tau still maintain neuronal nuclei
(NeuN) despite changes in nuclear morphology (hematoxylin) and in content of Nissl substance (lower panels).
4. Conclusions
Based on the combination of transgenic and viral models,
and taking into account pathological and clinical data from
humanpatients,wedefendthethesisthatneurodegeneration
isnotcausedbyasingledefectbutby—atleast—dualactions
(Figure 4).
The ﬁrst is proposed to be intrinsically neuronal, for
example, damage by accumulation of endogenous proteins
in various molecular forms. In the case discussed here,
protein Tau is the cause in primary Tauopathies. In AD, the
upstream triggers are the amyloid peptides that accumulate
because of mutations or other imposed defects in the
proteolytic machinery that controls their formation and
turnover.
The second factor is also essential, and can be neuronal
or microglial in origin, related to any type of stress the
brain can experience or has to endure, that is, partial
hypoxia, glucose overload or shortage, problems with lipid
or cholesterol, or other essential metabolites. The thesis is
supported by clinical, but mainly experimental observations.
For one, all available data convinced us that the “macro”
protein-aggregates, that is, plaques and tangles, are not the
most essential in causing cognitive defects and dementia.
The challenge to deﬁne the neurotoxic Tau-species and its
mode of action does nevertheless become not less compli-
cated.
The combination of transgenic and viral models illus-
trates eloquently the power of the approach as well as its
weaknesses. We still have more modeling to do, taking
into account the data and indications that are provided by
ongoing clinical studies, because only the human patient can
eventually conﬁrm any hypothesis based on experimental
models.
Acknowledgments
The investigations were made possible by funding and
support from the Fonds voor Wetenschappelijk Onderzoek-
Vlaanderen (FWO-Vlaanderen), the Instituut voor Weten-
schap en Techniek (IWT), the EEC-6th and 7th Frame-
work Programs, the Rooms-fund, the KULeuven-Research
Fund (BOF), and KULeuven-Research&Development. The
authors sincerely thank many collaborators and scientists
for technical assistance, advice, materials, and scientiﬁc
or moral support. T. Jaworski was the recipient of EU-
Marie Curie doctoral Fellowship (MEST-CT-2005-020589—
EURON PhD School for Neurosciences).8 International Journal of Alzheimer’s Disease
− +
− +
Physiology
AAV-tau Starving synapses
Synaptic decay
GSK3b Li+
Cargo containing synaptic vesicle
Mitochondrium
Kinesin light chain
Kinesin heavy chain
tubulin
Tau
P-tau
Microglia activation (fractalkine, ATP, UDP?)
Blood brain barrier
Anterograde
Retrograde
∗
∗
∗ ∗
Toxic gain of function
TauxGSK3b
Figure 4: Model for Tau-mediated neurodegeneration. In normal conditions, protein Tau is regulated tightly at diﬀerent levels: isoform
expression, phosphorylation, microtubule binding, turnover, all needed to ensure normal transport along microtubules in axons and
dendrites (upper panel). Increased expression of protein Tau, either genetically or pathologically in humans or experimentally in
animal models will increase the amount of protein Tau bound to microtubules, thereby competing for and blocking the binding-
sites needed for the motor proteins that carry out transport (middle panel). The resulting impairment in transport of any cargo,
from synaptic vesicles and mitochondria to proteins, will impair any transport and energy-dependent processes at the synapses, which
will extend and evolve into degenerating neuronal processes, and eventually lead to neuronal death. Defective synaptic transmission
is then expected to be an early indication or symptom. Initially, small and loose aggregates or oligomers of protein Tau collect onto
the microtubules, causing them to disintegrate or collapse. We also propose that the injured neuronal processes release proteins and
factors, purposely or accidental that contribute to the activation of microglia and astroglia. The activated inﬂammatory cells secrete
then factors that aﬀect not only neurons but also other cells that constitute the unit blood-brain-barrier, provoking higher permeability,
which further negatively aﬀects neurons [11, 30]. Interesting is the connection to increased activity of GSK3, which rescued the
axonopathy of Tau4R mice and the premature death of Tau.P301L mice by phosphorylating protein Tau and thereby detach it from
the microtubuli to restore normal transport by motor proteins (lower panel) [26, 37]. Likewise, neither cell-death nor inﬂammation
is provoked by AAV-Tau.255, devoid of the microtubule binding domain. The transgenic and viral models thereby underscore the
microtubule binding of protein Tau as the common mechanism of action whereby protein Tau is causing neuronal demise and eventually
neurodegeneration.International Journal of Alzheimer’s Disease 9
References
[1] I. Dewachter and F. Van Leuven, “Secretases as targets for
the treatment of Alzheimer’s disease: the prospects,” Lancet
Neurology, vol. 1, no. 7, pp. 409–416, 2002.
[2] C. Haass, “Take ﬁve—BACE and the γ-secretase quartet
conduct Alzheimer’s amyloid β-peptide generation,” EMBO
Journal, vol. 23, no. 3, pp. 483–488, 2004.
[3] D.M.WalshandD.J.Selkoe,“Decipheringthemolecularbasis
of memory failure in Alzheimer’s disease,” Neuron, vol. 44, no.
1, pp. 181–193, 2004.
[ 4 ]C .G .G l a b ea n dR .K a y e d ,“ C o m m o ns t r u c t u r ea n dt o x i c
function of amyloid oligomers implies a common mechanism
of pathogenesis,” Neurology, vol. 66, no. 2, pp. S74–S78, 2006.
[5] S. Lesn´ e, M. T. Koh, L. Kotilinek et al., “A speciﬁc amyloid-β
protein assembly in the brain impairs memory,” Nature, vol.
440, no. 7082, pp. 352–357, 2006.
[6] D. Moechars, I. Dewachter, K. Lorent et al., “Early phenotypic
changes in transgenic mice that overexpress diﬀerent mutants
of amyloid precursor protein in brain,” Journal of Biological
Chemistry, vol. 274, no. 10, pp. 6483–6492, 1999.
[7] F. Van Leuven, “Single and multiple transgenic mice as models
for Alzheimer’s disease,” Progress in Neurobiology, vol. 61, no.
3, pp. 305–312, 2000.
[8] I. Dewachter, D. Moechars, J. Van Dorpe et al., “Modelling
Alzheimer’s disease in multiple transgenic mice,” Biochemical
Society Symposium, vol. 67, pp. 203–210, 2001.
[9] D. Terwel, I. Dewachter, and F. Van Leuven, “Axonal transport,
tau protein, and neurodegeneration in Alzheimer’s disease,”
NeuroMolecular Medicine, vol. 2, no. 2, pp. 151–165, 2002.
[10] T. Van Dooren, I. Dewachter, P. Borghgraef, and F. Van
Leuven, “Transgenic mouse models for APP processing and
Alzheimer’s disease: early and late defects,” Sub-Cellular
Biochemistry, vol. 38, pp. 45–63, 2005.
[11] T. Jaworski, I. Dewachter, C. M. Seymour et al., “Alzheimer’s
disease: old problem, new views from transgenic and viral
models,” Biochimica et Biophysica Acta. In press.
[12] M. A. Mintun, G. N. Larossa, Y. I. Sheline et al., “[11C]PIB
in a nondemented population: potential antecedent marker
of Alzheimer disease,” Neurology, vol. 67, no. 3, pp. 446–452,
2006.
[13] A. Nordberg, “Amyloid plaque imaging in vivo: current
achievement and future prospects,” European Journal of
Nuclear Medicine and Molecular Imaging,v o l .3 5 ,n o .1 ,p p .
S46–S50, 2008.
[14] W. E. Klunk and C. A. Mathis, “The future of amyloid-
beta imaging: a tale of radionuclides and tracer proliferation,”
Current Opinion in Neurology, vol. 21, no. 6, pp. 683–687,
2008.
[15] A. Delacourte and L. Buee, “Tau pathology: a marker of
neurodegenerative disorders,” Current Opinion in Neurology,
vol. 13, no. 4, pp. 371–376, 2000.
[ 1 6 ]V .M . - Y .L e e ,M .G o e d e r t ,a n dJ .Q .T r o j a n o w s k i ,“ N e u r o d e -
generative tauopathies,” Annual Review of Neuroscience, vol.
24, pp. 1121–1159, 2001.
[17] C. Duyckaerts, B. Delatour, and M.-C. Potier, “Classiﬁcation
and basic pathology of Alzheimer disease,” Acta Neuropatho-
logica, vol. 118, no. 1, pp. 5–36, 2009.
[18] A. C. Ludolph, J. Kassubek, B. G. Landwehrmeyer et
al., “Tauopathies with parkinsonism: clinical spectrum,
neuropathologic basis, biological markers, and treatment
options,” European Journal of Neurology, vol. 16, no. 3, pp.
297–309, 2009.
[19] P.Heutink,“Untanglingtau-relateddementia,”HumanMolec-
ular Genetics, vol. 9, no. 6, pp. 979–986, 2000.
[20] E. M. Ingram and M. G. Spillantini, “Tau gene mutations:
dissecting the pathogenesis of FTDP-17,” Trends in Molecular
Medicine, vol. 8, no. 12, pp. 555–562, 2002.
[21] D. H. Geschwind, “Tau phosphorylation, tangles, and neu-
rodegeneration: the chicken or the egg?” Neuron, vol. 40, no.
3, pp. 457–460, 2003.
[22] J. Hardy and D. Allsop, “Amyloid deposition as the central
event in the aetiology of Alzheimer’s disease,” Trends in
Pharmacological Sciences, vol. 12, no. 10, pp. 383–388, 1991.
[23] J. Lewis, D. W. Dickson, W.-L. Lin et al., “Enhanced neuroﬁb-
rillary degeneration in transgenic mice expressing mutant tau
and APP,” Science, vol. 293, no. 5534, pp. 1487–1491, 2001.
[24] S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic
model of Alzheimer’s disease with plaques and tangles:
intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39,
no. 3, pp. 409–421, 2003.
[25] D. Muyllaert, D. Terwel, P. Borghgraef, H. Devijver, I.
Dewachter, and F. Van Leuven, “Transgenic mouse models for
Alzheimer’s disease: the role of GSK-3β in combined amyloid
and tau-pathology,” Revue Neurologique, vol. 162, no. 10, pp.
903–907, 2006.
[26] D. Terwel, D. Muyllaert, I. Dewachter et al., “Amyloid activates
GSK-3β to aggravate neuronal tauopathy in bigenic mice,”
American Journal of Pathology, vol. 172, no. 3, pp. 786–798,
2008.
[ 2 7 ]E .D .R o b e r s o n ,K .S c e a r c e - L e v i e ,J .J .P a l o pe ta l . ,“ R e d u c i n g
endogenous tau ameliorates amyloid β-induced deﬁcits in an
Alzheimer’s disease mouse model,” Science, vol. 316, no. 5825,
pp. 750–754, 2007.
[28] D. Paquet, B. Schmid, and C. Haass, “Transgenic zebraﬁsh as a
novel animal model to study tauopathies and other neurode-
generative disorders in vivo,” Neurodegenerative Diseases, vol.
7, no. 1–3, pp. 99–102, 2010.
[29] V. Khurana, “Modeling tauopathy in the fruit ﬂy Drosophila
melanogaster,”JournalofAlzheimer’sDisease,v ol.15,no .4,pp .
541–553, 2008.
[30] T. Jaworski, I. Dewachter, B. Lechat et al., “AAV-tau mediates
pyramidal neurodegeneration by cell-cycle re-entry without
neuroﬁbrillarytangleformationinwild-typemice,”PLoSOne,
vol. 4, no. 10, Article ID e7280, 2009.
[31] Z. Shevtsova, J. M. I. Malik, U. Michel, M. B¨ ahr, and S. K¨ ugler,
“Promoters and serotypes: targeting of adeno-associated virus
vectors for gene transfer in the rat central nervous system in
vitro and in vivo,” Experimental Physiology,v o l .9 0 ,n o .1 ,p p .
53–59, 2005.
[32] S.K¨ ugler,R.Hahnewald,M.Garrido,andJ.Reiss,“Long-term
rescue of a lethal inherited disease by adeno-associated virus-
mediated gene transfer in a mouse model of molybdenum-
cofactor deﬁciency,” American Journal of Human Genetics, vol.
80, no. 2, pp. 291–297, 2007.
[33] A. Goate, M.-C. Chartier-Harlin, M. Mullan et al., “Segrega-
tion of a missense mutation in the amyloid precursor protein
gene with familial Alzheimer’s disease,” Nature, vol. 349, no.
6311, pp. 704–706, 1991.
[34] S. Kumar-Singh, C. De Jonghe, M. Cruts et al., “Nonﬁb-
rillar diﬀuse amyloid deposition due to a γ42-secretase site
mutation points to an essential role for N-truncated Aβ42 in
Alzheimer’sdisease,”HumanMolecularGenetics,vol.9,no.18,
pp. 2589–2598, 2000.10 International Journal of Alzheimer’s Disease
[35] M. Citron, T. Oltersdorf, C. Haass et al., “Mutation of the
β-amyloid precursor protein in familial Alzheimer’s disease
increases β-protein production,” Nature, vol. 360, no. 6405,
pp. 672–674, 1992.
[36] D.Terwel,R.Lasrado,J.Snauwaertetal.,“Changedconforma-
tion of mutant tau-P301L underlies the moribund tauopathy,
absent in progressive, nonlethal axonopathy of tau-4R/2N
transgenic mice,” Journal of Biological Chemistry, vol. 280, no.
5, pp. 3963–3973, 2005.
[37] K. Spittaels, C. Van Den Haute, J. Van Dorpe et al., “Glycogen
synthase kinase-3β phosphorylates protein tau and rescues the
axonopathy in the central nervous system of human four-
repeat tau transgenic mice,” Journal of Biological Chemistry,
vol. 275, no. 52, pp. 41340–41349, 2000.
[38] R. L. Klein, R. D. Dayton, C. G. Diaczynsky, and D. B. Wang,
“Pronouncedmicrogliosis andneurodegeneration inaged rats
after tau gene transfer,” Neurobiology of Aging. In press.
[39] D. Muyllaert, D. Terwel, A. Kremer et al., “Neurodegeneration
and neuroinﬂammation in cdk5/p25-inducible mice: a model
for hippocampal sclerosis and neocortical degeneration,”
American Journal of Pathology, vol. 172, no. 2, pp. 470–485,
2008.
[40] C. Van den Haute, K. Spittaels, J. Van Dorpe et al., “Coexpres-
sion of human cdk5 and its activator p35 with human protein
tauinneuronsinbrainoftripletransgenicmice,”Neurobiology
of Disease, vol. 8, no. 1, pp. 32–44, 2001.
[41] T. Vandebroek, D. Terwel, T. Vanhelmont et al., “Microtubule
binding and clustering of human Tau-4R and Tau-P301L
proteins isolated from yeast deﬁcient in orthologues of
glycogen synthase kinase-3β or cdk5,” Journal of Biological
Chemistry, vol. 281, no. 35, pp. 25388–25397, 2006.
[42] T. G´ omez-Isla, R. Hollister, H. West et al., “Neuronal loss cor-
relates with but exceeds neuroﬁbrillary tangles in Alzheimer’s
disease,” Annals of Neurology, vol. 41, no. 1, pp. 17–24, 1997.
[43] J. J. Kril, S. Patel, A. J. Harding, and G. M. Halliday,
“Neuron loss from the hippocampus of Alzheimer’s disease
exceeds extracellular neuroﬁbrillary tangle formation,” Acta
Neuropathologica, vol. 103, no. 4, pp. 370–376, 2002.
[44] K. Santacruz, J. Lewis, T. Spires et al., “Tau suppression in a
neurodegenerativemousemodelimprovesmemoryfunction,”
Science, vol. 309, no. 5733, pp. 476–481, 2005.
[45] T. L. Spires, J. D. Orne, K. SantaCruz et al., “Region-speciﬁc
dissociation of neuronal loss and neuroﬁbrillary pathology in
a mouse model of tauopathy,” American Journal of Pathology,
vol. 168, no. 5, pp. 1598–1607, 2006.
[46] S. Feuillette, L. Miguel, T. Fr´ ebourg, D. Campion, and
M. Lecourtois, “Drosophila models of human tauopathies
indicatethatTauproteintoxicityinvivoismediatedbysoluble
cytosolic phosphorylated forms of the protein,” Journal of
Neurochemistry, vol. 113, no. 4, pp. 895–903, 2010.
[47] R. Morsch, W. Simon, and P. D. Coleman, “Neurons may
live for decades with neuroﬁbrillary tangles,” Journal of
Neuropathology andExperimentalNeurology, vol. 58, no.2, pp.
188–197, 1999.
[48] A. de Calignon, T. L. Spires-Jones, R. Pitstick, G. A. Carlson,
and B. T. Hyman, “Tangle-bearing neurons survive despite
disruption of membrane integrity in a mouse model of
tauopathy,” Journal of Neuropathology and Experimental Neu-
rology, vol. 68, no. 7, pp. 757–761, 2009.
[49] W. H. Yu, A. M. Cuervo, A. Kumar et al., “Macroautophagy—
an o v e lβ-amyloid peptide-generating pathway activated in
Alzheimer’s disease,” J o u rn a lo fC ellB i o l o gy , vol. 171, no. 1, pp.
87–98, 2005.
[50] Y.Wang,M.Martinez-Vicente,U.Kr¨ ugeretal.,“Taufragmen-
tation, aggregation and clearance: the dual role of lysosomal
processing,” Human Molecular Genetics, vol. 18, no. 21, pp.
4153–4170, 2009.
[51] L. Li, X. Zhang, and W. Le, “Autophagy dysfunction in
Alzheimer’s disease,” Neurodegenerative Diseases, vol. 7, no. 4,
pp. 265–271, 2010.
[52] M. Garc´ ıa-Arencibia, W. E. Hochfeld, P. P. C. Toh, and D. C.
Rubinsztein, “Autophagy, a guardian against neurodegenera-
tion,” Seminars in Cell and Developmental Biology. In press.
[53] A. Caccamo, S. Majumder, A. Richardson, R. Strong, and S.
Oddo, “Molecular interplay between mammalian target of
rapamycin (mTOR), amyloid-β, and Tau: eﬀects on cognitive
impairments,” Journal of Biological Chemistry, vol. 285, no. 17,
pp. 13107–13120, 2010.
[54] E. Braak and H. Braak, “Alzheimer’s disease: transiently
developing dendritic changes in pyramidal cells of sector CA1
of the Ammon’s horn,” Acta Neuropathologica, vol. 93, no. 4,
pp. 323–325, 1997.
[55] Y. Yoshiyama, M. Higuchi, B. Zhang et al., “Synapse loss and
microglial activation precede tangles in a P301S tauopathy
mouse model,” Neuron, vol. 53, no. 3, pp. 337–351, 2007.
[56] D. C. David, S. Hauptmann, I. Scherping et al., “Proteomic
and functional analyses reveal a mitochondrial dysfunction in
P301L tau transgenic mice,” Journal of Biological Chemistry,
vol. 280, no. 25, pp. 23802–23814, 2005.
[57] V. Rhein, X. Song, A. Wiesner et al., “Amyloid-β and tau
synergistically impair the oxidative phosphorylation system in
triple transgenic Alzheimer’s disease mice,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 106, no. 47, pp. 20057–20062, 2010.
[58] K. Spittaels, C. Van den Haute, J. Van Dorpe et al., “Prominent
axonopathy in the brain and spinal cord of transgenic mice
overexpressing four-repeat human tau protein,” American
Journal of Pathology, vol. 155, no. 6, pp. 2153–2165, 1999.
[59] D. Muyllaert, A. Kremer, T. Jaworski et al., “Glycogen synthase
kinase-3β, or a link between amyloid and tau pathology?”
Genes, Brain and Behavior, vol. 7, no. 1, pp. 57–66, 2008.
[60] L. Arnaud, N. K. Robakis, and M. E. Figueiredo-Pereira, “It
may take inﬂammation, phosphorylation and ubiquitination
to ’tangle’ in Alzheimer’s disease,” Neurodegenerative Diseases,
vol. 3, no. 6, pp. 313–319, 2007.
[61] K. M. Lucin and T. Wyss-Coray, “Immune activation in brain
agingandneurodegeneration:toomuchortoolittle?”Neuron,
vol. 64, no. 1, pp. 110–122, 2009.